PSMA-targeted Radioligand Therapy (PRLT) is a form of molecular targeted therapy that is performed by using the prostate-specific membrane antigen coupled with a radionuclide emitting beta radiation. In this case the isotope Lutitium-177. 

PRLT is a realtively new novel nuclear medicine therapy.  This form of therapy was first applied to metatstatic prostate tumors at Bad Berka in 2013.